An Open-Label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism

CONCLUSION: Eneboparatide allowed independence from conventional therapy and maintenance of serum calcium within a target range, while normalizing uCa excretion and producing a balanced resumption of bone turnover.PMID:38449442 | DOI:10.1210/clinem/dgae121

Source: The Journal of Clinical Endocrinology and Metabolism - March 7, 2024 Category: Endocrinology Authors: Istvan Takacs Emese Mezosi Alfonso Soto Peter Kamenick ý Lucile Figueres Maria Angeles Galvez Moreno Sandrine Lemoine Francoise Borson-Chazot Ismael Capel Taha Ouldrouis Nad ège Lucas Soraya Allas Mark Sumeray Michel Ovize Michael Mannstadt Source Type: research